Stoloff Stuart W
Family and Community Medicine, University of Nevada, School of Medicine, Reno, Nevada, USA.
Clin Cornerstone. 2008;9(2):6-20; discussion 21-3. doi: 10.1016/s1098-3597(09)62036-6.
The continuing evolution of asthma treatment and prevention are reflected in updated guidelines from the National Asthma Education and Prevention Program and Global Initiative for Asthma as well as other recent publications. The 2007 Expert Panel Report 3 guidelines designate severity and control, mediated by considerations of current impairment and future risk, as the primary concepts in assessing and monitoring asthma. Severity should ideally be determined at the time of diagnosis, after which control becomes the central focus of asthma management. In the area of treatment, inhaled corticosteroids (ICSs) remain first-line therapy for long-term asthma management in children and adults. For patients whose severity of asthma requires more than low-dose ICSs, or whose asthma cannot be well controlled on monotherapy with low-dose ICSs, evidence supports the efficacy of combination therapy consisting of an ICS plus an inhaled long-acting beta(2)-agonist (LABA) or an increase to medium-dose ICSs. For children >5 years of age and adults not controlled on low-dose ICSs, the combination of a low-dose ICS plus an inhaled LABA is equivalent in terms of outcomes to the use of medium-dose ICS. For children <5 years of age not controlled on low-dose ICSs, increasing the dose of ICSs is preferred to the addition of a LABA to low-dose ICS therapy as no studies using combination therapy have been conducted for patients in this age group. With regard to asthma prevention, approaches to primary prevention (to avoid allergen sensitization) and secondary prevention (to avoid disease progression) are still very much in the developmental stage, while tertiary prevention (to avoid asthmatic stimuli) has been more successful particularly in pediatric patients. Written action plans as part of self-management processes appear to improve physician-patient communication and disease status tracking. Other considerations in successful asthma management include patient education and monitoring of adherence to treatment regimens.
国家哮喘教育与预防计划及全球哮喘防治创议组织发布的最新指南以及其他近期出版物都反映出哮喘治疗与预防领域的持续发展。2007年专家小组报告3指南将由当前损伤和未来风险考量所介导的严重程度和控制情况,指定为评估和监测哮喘的主要概念。理想情况下,应在诊断时确定严重程度,此后控制便成为哮喘管理的核心重点。在治疗方面,吸入性糖皮质激素(ICSs)仍然是儿童和成人长期哮喘管理的一线疗法。对于哮喘严重程度需要超过低剂量ICSs的患者,或者仅用低剂量ICSs单药治疗无法良好控制哮喘的患者,有证据支持由ICS加吸入性长效β2受体激动剂(LABA)组成的联合疗法或增加至中剂量ICSs的疗效。对于5岁以上儿童和使用低剂量ICSs无法控制的成人,低剂量ICS加吸入性LABA联合疗法在治疗效果上等同于使用中剂量ICS。对于使用低剂量ICSs无法控制的5岁以下儿童,增加ICSs剂量优于在低剂量ICS治疗中添加LABA,因为尚未针对该年龄组患者开展联合疗法的研究。关于哮喘预防,一级预防(避免变应原致敏)和二级预防(避免疾病进展)的方法仍处于非常早期的发展阶段,而三级预防(避免哮喘刺激)则更为成功,尤其在儿科患者中。作为自我管理流程一部分的书面行动计划似乎能改善医患沟通和疾病状态跟踪。成功的哮喘管理中的其他考量因素包括患者教育以及对治疗方案依从性的监测。